Zobrazeno 1 - 10
of 241
pro vyhledávání: '"Katsushi Tanaka"'
Autor:
Kohei Somekawa, Keisuke Watanabe, Kenichi Seki, Suguru Muraoka, Ami Izawa, Ayami Kaneko, Yukiko Otsu, Momo Hirata, Sousuke Kubo, Katsushi Tanaka, Ryo Nagasawa, Hiromi Matsumoto, Kota Murohashi, Hiroaki Fuji, Ayako Aoki, Nobuyuki Horita, Yu Hara, Nobuaki Kobayashi, Makoto Kudo, Takeshi Kaneko
Publikováno v:
European Clinical Respiratory Journal, Vol 11, Iss 1 (2024)
Background Biologics are the important drugs for severe asthma, but clinical trials included few elderly patients. Data on the safety and efficacy of benralizumab in elderly asthma patients are limited.Methods This clinical study was a multicentre, r
Externí odkaz:
https://doaj.org/article/3a61695cb0444719be9e00172eb6d4dd
Autor:
Hiromi Matsumoto, Taichi Fukushima, Nobuaki Kobayashi, Yuuki Higashino, Suguru Muraoka, Yukiko Ohtsu, Momo Hirata, Kohei Somekawa, Ayami Kaneko, Ryo Nagasawa, Sousuke Kubo, Katsushi Tanaka, Kota Murohashi, Hiroaki Fujii, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko
Publikováno v:
PLoS ONE, Vol 19, Iss 8, p e0299760 (2024)
BackgroundImmune checkpoint inhibitors (ICIs) have improved outcomes in cancer treatment but are also associated with adverse events and financial burdens. Identifying accurate biomarkers is crucial for determining which patients are likely to benefi
Externí odkaz:
https://doaj.org/article/2eee71d6b23e44f4881ae7b437149737
Autor:
Hiromi Matsumoto, Kohei Somekawa, Nobuyuki Horita, Suguru Ueda, Megumi Kaneko, Ayami Kaneko, Nobuhiko Fukuda, Ami Izawa, Chisato Kamimaki, Katsushi Tanaka, Kota Murohashi, Hiroaki Fuji, Yoichi Tagami, Ayako Aoki, Keisuke Watanabe, Yu Hara, Nobuaki Kobayashi, Takeshi Kaneko
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Immune checkpoint inhibitors (ICIs) have shown remarkable therapeutic outcomes among cancer patients. Durvalumab plus tremelimumab (DT) is under investigation as a new ICI combination therapy, and its efficacy has been reported in various
Externí odkaz:
https://doaj.org/article/f2782d0658c74753a0c72f09f3b0eff8
Autor:
Hiroaki Fujii, Hideyuki Nagakura, Nobuaki Kobayashi, Sousuke Kubo, Katsushi Tanaka, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Masanori Nishikawa, Kenji Miura, Harumi Koizumi, Yu Ito, Motofumi Tsubakihara, Naoki Miyazawa, Makoto Kudo, Masaharu Shinkai, Takeshi Kaneko
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background This study aimed to determine the effectiveness of liquid biopsy in detecting epidermal growth factor receptor (EGFR) mutations at diagnosis, disease progression, and intermediate stages. Methods This prospective, multicenter, obs
Externí odkaz:
https://doaj.org/article/0d1ed5d6ba3e4abdb7bde27213426679
Autor:
Hiromi Matsumoto, Nobuaki Kobayashi, Kohei Somekawa, Nobuhiko Fukuda, Ayami Kaneko, Chisato Kamimaki, Sousuke Kubo, Katsushi Tanaka, Yoichi Tagami, Shuhei Teranishi, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Masaki Yamamoto, Makoto Kudo, Harumi Koizumi, Kenji Miura, Naoki Miyazawa, Takeshi Kaneko
Publikováno v:
Thoracic Cancer, Vol 13, Iss 2, Pp 228-235 (2022)
Abstract Background Pembrolizumab alone or in combination with chemotherapy is a standard treatment for patients with non‐small‐cell lung cancer (NSCLC) with high programmed death‐ligand 1 (PD‐L1) expression. However, no study has compared th
Externí odkaz:
https://doaj.org/article/fd6bfdefa2b642d0bb06602450fe2586
Autor:
Miki Hoshi, Nobuaki Kobayashi, Katsushi Tanaka, Kohei Somekawa, Ayami Kaneko, Ami Izawa, Kenichi Seki, Yoichi Tagami, Ayako Aoki, Hiroaki Fujii, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Mai Matsumura, Makiko Enaka, Maki Hagihara, Takeshi Kaneko
Publikováno v:
Thoracic Cancer, Vol 12, Iss 23, Pp 3281-3285 (2021)
Abstract Lung lesions of Hodgkin's lymphoma (HL) are rare and difficult to diagnose by nonsurgical biopsy. We herein present the case of a 72‐year‐old Japanese male who presented with accumulation of lung infiltrates and masses bilaterally on the
Externí odkaz:
https://doaj.org/article/6f81bcc3cafb4118927952b19b4fd5cc
Autor:
Nobuaki Kobayashi, Seigo Katakura, Chisato Kamimaki, Kohei Somekawa, Nobuhiko Fukuda, Katsushi Tanaka, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Hongmei Piao, Takeshi Kaneko
Publikováno v:
Thoracic Cancer, Vol 12, Iss 7, Pp 1096-1105 (2021)
Abstract Background Differences in the resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations are unknown. This m
Externí odkaz:
https://doaj.org/article/e7d7e3b79e634efbba3ba1366ad38f0a
Autor:
Seigo Katakura, Nobuaki Kobayashi, Hisashi Hashimoto, Chisato Kamimaki, Katsushi Tanaka, Sousuke Kubo, Kentaro Nakashima, Shuhei Teranishi, Saki Manabe, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Masaki Yamamoto, Makoto Kudo, Hongmei Piao, Takeshi Kaneko
Publikováno v:
Thoracic Cancer, Vol 11, Iss 10, Pp 2975-2982 (2020)
Background Advanced non‐small cell lung cancer (NSCLC) has a high mortality rate and poor prognosis. However, outcomes have gradually improved after the introduction of novel immunotherapies, including immune checkpoint inhibitors (ICIs). Although
Externí odkaz:
https://doaj.org/article/16617066622c41d597b7c6fc08914603
Autor:
Nobuaki Kobayashi, Hisashi Hashimoto, Chisato Kamimaki, Ryo Nagasawa, Katsushi Tanaka, Sousuke Kubo, Seigo Katakura, Hao Chen, Nobuyuki Hirama, Ryota Ushio, Ayako Aoki, Kentaro Nakashima, Shuhei Teranishi, Saki Manabe, Hiroki Watanabe, Nobuyuki Horita, Keisuke Watanabe, Yu Hara, Masaki Yamamoto, Makoto Kudo, Hongmei Piao, Takeshi Kaneko
Publikováno v:
Thoracic Cancer, Vol 11, Iss 8, Pp 2125-2129 (2020)
Introduction As most patients with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) develop progressive disease after treatment with osimertinib, it is important to develop more effective treatment options. Afatin
Externí odkaz:
https://doaj.org/article/087b6fea136f41399c90d1366b3a7289
Autor:
Fumihiro Ogawa, Yasufumi Oi, Hiroshi Honzawa, Naho Misawa, Tomoaki Takeda, Yushi Kikuchi, Ryosuke Fukui, Katsushi Tanaka, Daiki Kano, Hideaki Kato, Takeru Abe, Ichiro Takeuchi
Publikováno v:
PLoS ONE, Vol 17, Iss 10, p e0273134 (2022)
BackgroundThe outcomes of coronavirus disease 2019 (COVID-19) treatment have improved due to vaccination and the establishment of better treatment regimens. However, the emergence of variants of the severe acute respiratory syndrome coronavirus 2 (SA
Externí odkaz:
https://doaj.org/article/e1eea3f405fe4fd09af0b968fd1a0c19